MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched Project Angie. The project is the company’s effort to advance psychedelics, including LSD, as a means of pain treatment.

The company is currently exploring two primary clinical indications for the treatment of pain. First, MindMed will initiate a study of LSD in a severe pain indication. It is in the process of preparing for a proof of concept study which it intends to submit to the US FDA in the second half of 2021.

MindMed is also evaluating a second indication in a common, often debilitating, chronic pain syndrome.

According to IQVIA, the global market for analgesics is expected to grow over US$31 billion by 2030. MindMed CEO J.R. Rahn relayed that Project Angie is related to the company’s mission to improve mental health and combat substance use. “If we can help to develop a new paradigm to treat pain, it may have the potential to greatly reduce the use of addictive medicines such as opioids currently ravaging society and its mental health,” said Rahn.

Earlier this year, MindMed also launched a clinical trial to combine LSD and MDMA, and began the study on LSD neutralizer technology that aims to stop the substance’s trip effects during therapy.

Mind Medicine Inc. last traded at US$3.38 on the Nasdaq.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Mind Medicine To Conduct $25.0 Million Bought Deal Financing

Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this...

Friday, October 9, 2020, 09:01:05 AM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM